Jefferies initiates IDEXX Laboratories stock with Buy rating on pet aging trends

Jefferies initiated coverage on IDEXX Laboratories (IDXX) with a Buy rating and a $625 price target, citing its global leadership in veterinary diagnostics and anticipated accelerated demand from aging pandemic pets beginning in 2027, which is expected to drive significant long-term growth. The firm believes IDXX's current valuation at 26 times earnings does not adequately reflect this predictable future growth, even as the company recently reported a Q1 2025 EPS beat and updated full-year guidance. This positive outlook is echoed by other analysts, who also raised price targets, highlighting IDXX's market dominance, continuous innovation, and ability to navigate economic challenges.

Analysis

Jefferies has initiated coverage on IDEXX Laboratories (IDXX) with a Buy rating and a $625 price target, underpinned by a long-term structural growth thesis. The core catalyst is an anticipated acceleration in demand for veterinary diagnostics beginning in 2027, driven by the large cohort of pets acquired during the pandemic entering their prime testing years. This view is supported by the company's recent Q1 2025 earnings, which saw an EPS of $2.96 beat the $2.86 forecast, and a subsequent upward revision to full-year EPS guidance to a range of $11.93 to $12.43. While Q1 revenue of $998.43 million slightly missed the $1 billion consensus, the company's high-margin consumables and software segments grew 9% year-over-year. The bullish outlook is echoed by other firms like BTIG and Leerink Partners, which raised price targets to $545 and $580 respectively, citing IDEXX's market dominance and innovation, including the rollout of its InVue Dx console with over 4,500 placements planned for 2025. Critically, Jefferies notes that IDEXX's current valuation at 26 times earnings is below its five-year average of 30, suggesting the market has not fully priced in this predictable, long-term growth reacceleration.

Key Decisions for Investors

• Investors with a long-term horizon should consider the structural growth narrative, as the primary catalyst from an aging pet population is not expected until 2027, potentially offering a favorable entry point given the stock's valuation discount to its historical average.
• Monitor execution on near-term drivers, specifically the company's ability to deliver the forecasted 6-7% interim organic sales growth and the successful placement of over 4,500 InVue Dx units in 2025.
• While the analyst consensus is strongly positive, note that the stock is trading near its 52-week high after a 29.73% six-month run, and the slight Q1 revenue miss warrants attention to future top-line performance against expectations.